Testing microRNA for pancreatic cancer diagnosis and treatment response
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at tiny molecules in your body (microRNA) to help doctors better diagnose pancreatic cancer, predict how it may progress, and understand how it responds to treatment. It may help guide more personalized care in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed biopsy showing pancreatic adenocarcinoma (a specific type of pancreatic cancer).
- Your cancer started as inoperable, meaning it cannot be removed with surgery at first (either locally advanced or metastatic).
- Your cancer can be measured on scans (there is something visible the study can track).
- Your day-to-day functioning is limited but not severely (ECOG 2 or less).
- You can provide the required samples/specimens and information for the study.
- You agree to join by signing an informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a method that analyzes your tumor's genes and grows a mini-tumor in a dish to find which drugs might work best for your metastatic pancreatic cancer. It aims to improve treatment choices by using these personalized tests.
This study looks at blood tests to find markers that may help detect and monitor pancreatic cancer. It compares people with pancreatic cancer to those with benign pancreatic conditions and healthy volunteers.
This trial uses a tiny DNA-based machine to detect tumor signals in your blood. It aims to improve how doctors diagnose pancreatic cancer, especially at an early stage.
This trial studies a new blood test that looks for cancer-specific immune cells after surgery for pancreatic cancer. It aims to see if the test can detect any remaining cancer cells earlier than standard methods, which could help guide further treatment decisions.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This trial studies a blood test that looks for tiny traces of cancer-related DNA (called ctDNA) in people with pancreatic cancer that can be removed with surgery. The goal is to see whether this test can better predict how the cancer behaves and guide treatment decisions around surgery.
Hear when a new Pancreatic Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.